← Back to Search

Monoclonal Antibody

PTX-35 for Solid Tumors

Phase 1
Waitlist Available
Led By Anthony W Tolcher, MD
Research Sponsored by Pelican Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights

Study Summary

This trial is testing a new antibody drug in patients with cancer that has spread and is no longer responding to standard treatments. The goal is to see if the new drug is safe and what the best dose is.

Eligible Conditions
  • Advanced Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Subjects With Any Treatment-emergent Adverse Events (TEAEs) During the Trial
Secondary outcome measures
Determine PK area under curve up to the last measurable concentration (AUClast)
Determine PK maximum concentration (Cmax)
Determine PK terminal elimination half-life (T1/2λz)
+3 more

Trial Design

6Treatment groups
Experimental Treatment
Group I: PTX-35 Dose Level 6Experimental Treatment1 Intervention
Dose Level 6: PTX-35 3.0 mg/kg
Group II: PTX-35 Dose Level 5Experimental Treatment1 Intervention
Dose Level 5: PTX-35 1.0 mg/kg
Group III: PTX-35 Dose Level 4Experimental Treatment1 Intervention
Dose Level 4: PTX-35 0.30 mg/kg
Group IV: PTX-35 Dose Level 3Experimental Treatment1 Intervention
Dose Level 3: PTX-35 0.10 mg/kg
Group V: PTX-35 Dose Level 2Experimental Treatment1 Intervention
Dose Level 2: PTX-35 0.03 mg/kg
Group VI: PTX-35 Dose Level 1Experimental Treatment1 Intervention
Dose Level 1: PTX-35 0.01 mg/kg

Find a Location

Who is running the clinical trial?

Pelican Therapeutics, Inc.Lead Sponsor
Anthony W Tolcher, MDPrincipal InvestigatorNext Oncology
1 Previous Clinical Trials
29 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are we still taking patients for this experiment?

"While this particular study isn't looking for any more participants at the moment, that may change in the future. According to the information found on clinicaltrials.gov, this trial was posted on June 4th, 2020 and was last updated on October 3rd, 2020. There are currently 2564 other trials actively recruiting patients."

Answered by AI

When will PTX-35 be available for general use?

"PTX-35 received a safety score of 1 because, as a Phase 1 trial, there is minimal clinical data to support its efficacy and safety."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
PTX-35 in Patients With Advanced Solid Tumors
2020. "PTX-35 in Patients With Advanced Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04430348.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top